These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18767892)

  • 21. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
    Towse A; Pritchard C
    Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficiency frontier approach to economic evaluation: will it help German policy making?
    Brouwer WB; Rutten FF
    Health Econ; 2010 Oct; 19(10):1128-31. PubMed ID: 20641141
    [No Abstract]   [Full Text] [Related]  

  • 26. The NICE reference case requirement: implications for drug manufacturers and health systems.
    Langley PC
    Pharmacoeconomics; 2004; 22(4):267-71. PubMed ID: 14974876
    [No Abstract]   [Full Text] [Related]  

  • 27. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A national policy for health care technology assessment.
    Perry S; Pillar B
    Med Care Rev; 1990; 47(4):401-17. PubMed ID: 10113012
    [No Abstract]   [Full Text] [Related]  

  • 30. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.
    Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P
    Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What decision-makers want and what they have been getting.
    McGregor M
    Value Health; 2006; 9(3):181-5. PubMed ID: 16689712
    [No Abstract]   [Full Text] [Related]  

  • 32. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NICE is dead; long live NICE.
    Chinthapalli K
    BMJ; 2013 Apr; 346():f2546. PubMed ID: 23615594
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmaceutical regulation: the early experience of the NHS National Institute for Clinical Excellence (NICE) appraisal process--where are we headed?
    Taylor R
    Value Health; 2001; 4(1):8-11. PubMed ID: 11704972
    [No Abstract]   [Full Text] [Related]  

  • 36. Considering the value associated with innovation in health technology appraisal decisions (deliberations): a NICE thing to do?
    Green C
    Appl Health Econ Health Policy; 2010; 8(1):1-5. PubMed ID: 20038189
    [No Abstract]   [Full Text] [Related]  

  • 37. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nice or not so nice.
    McColgan K
    J Perioper Pract; 2010 Nov; 20(11):386. PubMed ID: 21162353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.